Clinical trials: Complication of Dialysis
Healthy
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment
- Trial name
- NCT00637403
- Testing
- Megestrol acetate concentrated suspension 125 mg/mL
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
The primary objectives of this study were to determine the rate, extent, and routes of radioactivity excretion of [¹⁴C]etelcalcetide in feces, dialysate, and urine over time and to measure radioactivity concentrations in whole…
- Trial name
- NCT02054572
- Testing
- [¹⁴C]Etelcalcetide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Peritoneal Dialysis Complication, Ultrafiltration Failure
The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients
Patients with average or high average peritoneal glucose transport status be included in the study as mentioned in the inclusion and exclusion criteria.
- Trial name
- NCT04923295
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Palestinian Territories
- Volunteers
- 20 people
- Sponsor
- An-Najah National University
End-Stage Renal Disease
Chinese Medicine on Deferring Dialysis Initiation
Stage 5 chronic kidney disease (CKD), also end stage renal disease(ESRD), usually presents overt clinical symptoms and is a critical stage when patients are encountered with dialysis.
- Trial name
- C-MODDI (NCT02194946)
- Testing
- CM therapies, CKD-related management
- Where
- 29 sites in China
- Volunteers
- 875 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Peritoneal Dialysis Complication
Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients
Peritoneal dialysis patients worldwide account for about 11% of the global dialysis population. The global annual growth rate of peritoneal dialysis is estimated to be 8%, which is listed as the preferred method of renal…
- Trial name
- NCT05224466
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol, reducing in turn the risk of cardiovascular events.
- Trial name
- NCT04397653
- Testing
- Evolocumab, Ezetimibe
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Policlinico Casilino ASL RMB
CKD (Chronic Kidney Disease) Stage 5D, Uremia; Chronic
Studies on Adsorption International Learning Initiative Global
Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia
- Conditions
- CKD (Chronic Kidney Disease) Stage 5D, Uremia; Chronic, Uremic; Toxemia, Inflammation Chronic
- Trial name
- SAILING (NCT07123909)
- Testing
- Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Botkin Hospital
End Stage Kidney Disease
Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients
This study aims to examine the effect of 25 hydroxyvitamin D supplementation and a structured exercise program on the exercise capacity and quality of life of haemodialysis patients with 25 hydroxyvitamin D insufficiency.
- Trial name
- NCT00798993
- Testing
- Structured Exercise program, Cholecalciferol (25-Hydroxyvitamin D), Usual exercise
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Sir Charles Gairdner Hospital
Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD)
DIALysis With EXpanded Solute Removal
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is: 1) Does expanded hemodialysis reduce the risk of death from…
- Conditions
- Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), Chronic Kidney Disease Requiring Chronic Dialysis, Pragmatic Randomized Controlled Trial
- Trial name
- DIALEX (NCT06660277)
- Testing
- Super High-Flux Dialyzer, High-Flux Dialyzer
- Where
- 3 sites in Canada
- Volunteers
- 4,800 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic Renal Disease, Cardiovascular Disease
Dyslipidemia-related Risk Factors in Dialysis
In this study, we studied lipoprotein abnormalities-related variables as risk factors for the development of cardiovascular disease in patients on renal replacement therapies.We studied 96 dialyzed patients, 62 males and 34…
- Conditions
- Chronic Renal Disease, Cardiovascular Disease, Dyslipidemia
- Trial name
- NCT02072837
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
CKD Stage 4, CKD Stage 5
Frailty, Cognitive Function and Health-related Quality of Life in Older Adults With Advanced Chronic Kidney Disease.
This observational study explores the impact of cognitive impairment and frailty in older adults with advanced chronic kidney disease ].
- Conditions
- CKD Stage 4, CKD Stage 5, Frailty, Cognitive Impairment
- Trial name
- NCT05705011
- Where
- Romania
- Volunteers
- 240 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Kidney Failure, Chronic
Effect of Exercise With Virtual Reality in Hemodialysis Patients
Background. An increase in inflammatory biomarkers is associated with impaired kidney function and increased cardiovascular risk and mortality.
- Trial name
- NCT05606484
- Testing
- Exercise with non-immersive virtual reality, Exercise with a static pedal
- Volunteers
- 80 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Dialysis; Complications, Chronic Kidney Disease 5D
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
This study is a prospective, multicenter, parallel-controlled, open-label clinical trial, planned to be conducted across multiple research centers in various provinces and cities in China.
- Conditions
- Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia
- Trial name
- PANGU-stepup (NCT07045155)
- Testing
- The rHuEPO Monotherapy Group (Control Group), The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group), The Pegmolesatide Monotherapy Group (Experimental group)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
End Stage Renal Failure on Dialysis, Renal Failure
Study on Fistuloplasty Using Flow Measurement Guidance
Hypothesis: The primary objective of this study is to assess whether using a flow measurement device, in this case the Transonics flow device, as an end-point to interventional treatment of diseased dialysis fistulae can help…
- Trial name
- NCT01643733
- Testing
- Using Flow measurements to guide fistula angioplasty (Transonics)
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Richard Lindsay
Uremic Pruritus
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
- Trial name
- NCT03281538
- Testing
- CR845
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- Cara Therapeutics, Inc.
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Chronic Kidney Disease, Dialysis
Dose-finding Study of MCI-196
The Primary Objective of this study is to determine the initial starting doses of colestilan (MCI-196) in paediatric subjects with Chronic Kidney Disease Stage 5 on Dialysis and with Hyperphosphataemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814904
- Testing
- colestilan-L, colestilan-M, colestilan-H
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Renal Failure, ESRD
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
Chronic utilization of bio-incompatible peritoneal dialysis (PD) solution has been implicated as a cause of progressive loss of peritoneal permeability and recurrent fluid overload in PD patients.
- Conditions
- Renal Failure, ESRD, Cardiovascular Disease
- Trial name
- NCT00966615
- Testing
- double-chamber bag Stay-Safe Balance system, glucose-based dialysis solution
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- Chinese University of Hong Kong
Hemodialysis
CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the potential of physical withdrawal from CR845 upon treatment discontinuation after 3 weeks of IV administration at a dose of 0.5 mcg/kg in…
- Trial name
- NCT05533008
- Testing
- CR845 0.5 mcg/kg
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Cara Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.